
Anemoi offers the first cross-disciplinary approach to the treatment of viral respiratory infections (VRIs). The lungs are the route of entry and primary organs damaged by respiratory viruses. Anemoi’s prophylactic and therapeutic platforms directly treat the lungs. Our team of world-class scientists has a combined 85 years of experience in inflammation, immunology, and vaccine development. Anemoi has patents pending that will grant protection through 2040. Anemoi holds IP and strategic collaborative positions around the production of therapeutic molecules, the use of carrier platforms, and…
Annual Revenue$1M to $5M
Estimated OwnershipPrivateBuilt from contact records that share this company: name, job title, job level, job function and person location.
Turn cold outreach into meaningful business conversations.
Rated and recommended by professionals who expect more
Matching runs on fields we already have: industry, employee range, HQ location, ownership type, funding rounds, specialities. Results come live from the ReachStream directory.